An official website of the United States government
Home
SEER Inquiry System - Report
Produced: 03/21/2026 12:02 AM
Question 20230059
Inquiry Details
References:
WHO Class Hem & Lymph Tumors. 5th edition, Beta version 2
Question:
Histology--Heme and Lymphoid Neoplasms: How is histology coded for a diagnosis stated as MDS/AML (myelodysplastic syndrome/acute myeloid leukemia) per the international consensus classification (ICC)? See Discussion.
Discussion:
The final diagnosis on bone marrow biopsy was high grade myeloid stem cell neoplasm, 17% blasts by differential count. The pathologist further states that this could be classified as “MDS with increased blasts (MDS-IB2) per the WHO 5th edition classification, or MDS/AML per the international consensus classification (ICC).” FISH and cytogenetics revealed a loss of 7q, but no other AML-related genetic abnormalities. The physician confirms the patient has MDS/AML.
Answer:
Updated Answer July 2024
Code histology as myelodysplastic neoplasm with increased blasts (9983/3) based on the WHO Classification of Hematolymphoid Tumors, 5th edition, Beta version 2. WHO lists MDS with increased blasts-2 (MDS-IB2) as a subtype of 9983/3.
Terms coded to 9983/3 include
- Myelodysplastic neoplasm with increased blasts
- Myelodysplastic neoplasm with increased blasts-1
- Myelodysplastic neoplasm with increased blasts-2
- Myelodysplastic neoplasm with increased blasts and fibrosis
- Subtypes: MDS with increased blasts-1 (MDS-IB1); MDS with increased blasts-2 (MDS-IB2); MDS with increased blasts and fibrosis (MDS-F)
When differences exist between WHO and ICC, assign the histology based on the WHO Classification.
